Closed · HT942525BCRPBTA3 · CFDA 12.420 · Discretionary

DoD Breast Cancer Breakthrough Award Level 3

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
September 10, 2025
Close date
4
Expected awards

The verdict

DoD Breast Cancer Breakthrough Award Level 3 is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 4 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.

Varies
award range
Closed
application status
4
expected awards
12.420
CFDA program

Archived opportunity record

DoD Breast Cancer Breakthrough Award Level 3 is closed (last close September 10, 2025). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed September 10, 2025

Posted Apr 22 Closes Sep 10

Est. Total Funding

$25,200,000

Expected Awards

4

Instrument

Grant

Description

Summary: Supports promising research that has high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the fiscal year 2025 (FY25) Breast Cancer Research Program (BCRP) overarching challenges, unless adequate justification for exception is provided. Applications must address the challenge in a way that can lead to or make a breakthrough and have major impact. The FY25 Breakthrough Award mechanism contains three different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. The current program announcement discusses the Breakthrough Award Level 3.Distinctive Features:· For this funding mechanism, small-scale clinical trials are allowed but not required. Applications proposing projects with a clinical trial should be submitted under the Clinical Trial option.· The research team must include two or more breast cancer consumer advocates.· This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, applications may be withdrawn if both the initiating and partnering applications are not submitted by the full application deadline or if the initiating or partnering application is administratively withdrawn.

Catch-all / unrestricted eligibility mark · HT942525BCRPBTA3

Grants.gov marks DoD Breast Cancer Breakthrough Award Level 3 with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org

More from Defense Health Agency Contracting Activity - DHACA

Closed Closed September 22, 2026

DoW Neurofibromatosis Synergistic Idea Award

View →
Closed Closed September 22, 2026

DoW Neurofibromatosis Investigator-Initiated Research Award

View →
Closed Closed September 22, 2026

DoW Neurofibromatosis Research Academy – Scholar Award

View →
Closed Closed September 22, 2026

DoW Neurofibromatosis Exploration-Hypothesis Development Award

View →
Open Closes November 18, 2026

DOW Combat Readiness – Medical Research Program Translational Research Award

View →

What to do next

DoD Breast Cancer Breakthrough Award Level 3 is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants